Anika Therapeutics, Inc.

NasdaqGS:ANIK Stock Report

Market Cap: US$255.3m

Anika Therapeutics Management

Management criteria checks 3/4

Anika Therapeutics' CEO is Cheryl Blanchard, appointed in Feb 2020, has a tenure of 4.75 years. total yearly compensation is $4.46M, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 1.2% of the company’s shares, worth $3.05M. The average tenure of the management team and the board of directors is 3 years and 4.2 years respectively.

Key information

Cheryl Blanchard

Chief executive officer

US$4.5m

Total compensation

CEO salary percentage16.3%
CEO tenure4.8yrs
CEO ownership1.2%
Management average tenure3yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Aug 03
Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Mar 11

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Jun 25
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

May 28

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

CEO Compensation Analysis

How has Cheryl Blanchard's remuneration changed compared to Anika Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$74m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$4mUS$726k

-US$83m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$6mUS$695k

-US$15m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$2m

Dec 31 2021US$4mUS$668k

US$4m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$10mUS$548k

-US$24m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

US$11m

Mar 31 2020n/an/a

US$28m

Dec 31 2019US$187kn/a

US$27m

Sep 30 2019n/an/a

US$31m

Jun 30 2019n/an/a

US$29m

Mar 31 2019n/an/a

US$30m

Dec 31 2018US$167kn/a

US$19m

Compensation vs Market: Cheryl's total compensation ($USD4.46M) is above average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Cheryl's compensation has been consistent with company performance over the past year.

CEO

Cheryl Blanchard (60 yo)

4.8yrs

Tenure

US$4,459,800

Compensation

Dr. Cheryl Renee Blanchard, Ph. D. is Director of Elute, Inc. from May 2013. She serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She serves as Director o...

Leadership Team

NamePositionTenureCompensationOwnership
Cheryl Blanchard
President4.8yrsUS$4.46m1.2%
$ 3.1m
Anne Nunes
Senior VP & COO3.2yrsUS$1.01m0.092%
$ 234.9k
David Colleran
Executive VP4.7yrsUS$1.55m0.23%
$ 575.1k
Michael Levitz
Executive Officerless than a yearUS$1.65m0.32%
$ 818.4k
Stephen Griffin
Executive VPless than a yearno datano data
Ian McLeod
VP & Chief Accounting Officerno datano datano data
Mark Namaroff
Vice President of Investor Relationsno datano datano data
James Chase
Senior Vice President of International Sales & Marketing4.5yrsno datano data
Ben Joseph
Vice President of Commercial & Corporate Development2.8yrsno datano data
Lisa Funiciello
Vice President of Human Resources2.8yrsno datano data

3.0yrs

Average Tenure

53yo

Average Age

Experienced Management: ANIK's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cheryl Blanchard
President6.3yrsUS$4.46m1.2%
$ 3.1m
William Jellison
Independent Directorless than a yearno data0.018%
$ 47.1k
John Henneman
Independent Chair of the Board5.3yrsUS$249.81k0.20%
$ 521.8k
Susan L. Vogt
Independent Director6.1yrsUS$248.98k0.21%
$ 527.8k
Sheryl Conley
Independent Director3.1yrsUS$242.48k0.14%
$ 347.0k
Glenn Larsen
Independent Director9.8yrsUS$237.48k0.21%
$ 528.5k
Joseph Capper
Independent Directorless than a yearno datano data
Gary Fischetti
Independent Director1.6yrsUS$571.00k0.089%
$ 228.4k
Stephen Richard
Independent Director4.2yrsUS$248.98k0.19%
$ 486.9k

4.2yrs

Average Tenure

63yo

Average Age

Experienced Board: ANIK's board of directors are considered experienced (4.2 years average tenure).